相关实验视频
Updated: May 5, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.8K
异性GAA淘汰对高脂肪饮食诱导的肥胖和糖尿病前期小鼠的新陈代谢和空间肝脏转录组没有影响
Cameron P McCall1, Melina C Mancini1, Jaroslaw Staszkiewicz1
1Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Physiological reports
|March 20, 2025
概括
酸性α-葡萄糖酶 (GAA) 的异构结合性淘汰不会影响小鼠的肝脏代谢或代谢健康,即使被食高脂肪饮食. 空间转录学揭示了饮食诱导的肝细胞基因表达的变化.
科学领域:
- 代谢研究的研究.
- 自自是一种自的过程.
- 遗传学 遗传学 是一个
背景情况:
- 糖,通过酸α-葡萄糖酶 (GAA) 分解糖原,对于葡萄糖平衡至关重要.
- 虽然肠道GAA抑制有利于代谢健康,但外围GAA抑制,特别是肝脏的影响仍然不清楚.
研究的目的:
- 在正常和高脂肪饮食条件下的小鼠中,研究异构性GAA淘汰 (HetKO-GAA) 的代谢后果.
- 为了确定改变肝脏GAA水平是否会影响整体代谢健康和基因表达.
主要方法:
- 具有GAA异性淘汰的小鼠被食低脂肪或高脂肪饮食以诱导肥胖.
- 进行了全面的代谢评估,包括体重,葡萄糖耐受性,胰岛素作用和能量消耗.
- 肝脏空间转录学被用来分析肝细胞中的基因表达变化.
主要成果:
- 与野生型对照相比,HetKO-GAA小鼠在体重,葡萄糖耐受性,胰岛素敏感性,能量消耗,基质代谢或肝脏甘油三水平上没有显著差异.
- 高脂肪饮食在周围和周围肝细胞中降低了代谢通路的调节,在周围细胞中独特的降低了核糖体基因的调节.
- 与野生类型相比,空间转录学显示,HetKO-GAA小鼠的肝细胞转录组没有显著的变化.
结论:
- 异性GAA淘汰并不会影响肝脏代谢或代谢健康,即使是在饮食诱导的肥胖的情况下.
- 空间转录学确定了肝细胞基因表达的饮食依赖的显著变化,这表明了与肥胖相关的代谢功能障碍的潜在治疗标.
相关概念视频
02:41Lethal Alleles
11.3K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
11.3K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121